Bromfenac SodiumThird Party Manufacturing in India

Bromfenac Sodium works by reducing pain and inflammation in the eye, primarily following surgical interventions. As a nonsteroidal anti-inflammatory drug, it targets and blocks the activity of cyclooxygenase enzymes, specifically cyclooxygenase-1 and cyclooxygenase-2. These cellular enzymes are responsible for producing prostaglandins, which are key lipid mediators that trigger inflammatory responses, swelling, and pain signals in response to tissue trauma. By inhibiting these enzymes, Bromfenac Sodium significantly lowers prostaglandin levels within the ocular tissues, thereby minimizing postoperative swelling, conjunctival hyperemia, and relieving subjective patient discomfort. Unlike corticosteroid ophthalmic drops, Bromfenac Sodium does not typically elevate intraocular pressure or delay corneal wound healing, making it a highly effective and safer choice for post-surgical recovery and management. It is widely tolerated by patients undergoing ocular procedures, such as cataract extraction, and provides sustained anti-inflammatory benefits with a convenient once- or twice-daily dosing regimen that improves patient compliance during the critical postoperative period.

Therapeutic Uses

Bromfenac Sodium ophthalmic solution is prescribed for the treatment of:

• Postoperative Inflammation: Managing swelling, redness, and irritation inside the eye following cataract surgery.
• Postoperative Ocular Pain: Relieving pain and discomfort during the initial recovery phase after eye surgeries.
• Cystoid Macular Edema (CME): Preventing or treating macular swelling that can occur after cataract extraction.

Why Manufacturers Choose Bromfenac Sodium

Pharmaceutical distributors and third party buyers choose Bromfenac Sodium because of its high commercial stability and growing demand in the ophthalmic care sector. As cataract surgeries increase globally due to aging populations, the demand for highly stable, low-frequency dosing ophthalmic NSAIDs has grown significantly. Bromfenac Sodium stands out due to its superior ocular tissue penetration, which allows for effective therapeutic concentrations in the aqueous humor with minimal dosing compared to older NSAID alternatives.

For contract manufacturing in India, Bromfenac Sodium 0.09% eye drops represent a high-value, specialized product category. Ophthalmic manufacturing requires WHO-GMP certified cleanroom facilities with sterile blow-fill-seal (BFS) technology to ensure contamination-free liquid filling. Partnering with a reliable manufacturer like Celesta Healthcare allows distributors to access premium quality ophthalmic products that comply with strict IP, BP, and USP standards. This ensures high-margin growth for PCD franchise partners and export-oriented distributors looking to expand their eye care portfolio.